Drug Profile
Immune globulin - Nihon Pharmaceutical
Alternative Names: Dried polyethylene glycol-treated human immunoglobulin - Nihon Pharmaceutical; GLOVENIN-I; Immunoglobulin intravenous - Nihon Pharmaceutical; Kenketu Glovenin-I; Kenketu Glovenin-I-Nichiyaku; NPB-01; TAK-961Latest Information Update: 15 Dec 2022
Price :
$50
*
At a glance
- Originator Nihon Pharmaceutical
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Agammaglobulinaemia; Bullous pemphigoid; Chronic inflammatory demyelinating polyradiculoneuropathy; Guillain-Barre syndrome; Motor neuron disease; Pemphigus; Stevens-Johnson syndrome; Toxic epidermal necrolysis
- Phase III Encephalitis
- Phase II Neuromyelitis optica
Most Recent Events
- 03 Mar 2022 Phase-III clinical trials in Encephalitis (Treatment-resistant) in Japan (IV) (NCT05177939)
- 05 Jan 2022 Nihon Pharmaceutical plans a phase III trial for autoimmune Encephalitis (In adolescents, In adults, In the elderly, Treatment-experienced) (IV), in February 2022 (NCT05177939)
- 01 Sep 2015 Nihon Pharmaceutical completes a phase III trial for Chronic inflammatory demyelinating polyradiculoneuropathy in Japan (NCT01824251)